Fusion protein, ubiquitination system containing the same and application thereof
By inserting antigen peptides and nano-antibody at the substrate binding of E3 ligase, the problem of structural damage in the construction of E3 ligase library in the prior art was solved, and the effective evaluation of the degradation ability of target proteins was achieved, and E3 ligation was improved Accuracy of enzyme library screening and PROTAC development efficiency.
Patent Information
- Application Number
- CN202410993860.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the construction of the E3 ligase library, the structure is destroyed by replacing the substrate recognition domain of the E3 ligase, affecting the degradation efficiency of target proteins. Especially for CRL4 E3 ligases such as CRBN, the degradation efficiency is not ideal.
Small antigenic peptides are inserted at the substrate binding of E3 ligase and the specifically recognized nanobody is linked to the target protein to simulate the interaction between E3 ligase and substrate, and evaluate the degradation ability of E3 ligase to the target protein , ALFA peptide and NbALFAK2R nanobody are used to ensure structural integrity and enhance binding force.
It provides a detection method that does not destroy the structure of E3 ligase, which can effectively evaluate its degradation ability to target proteins, improves the accuracy and efficiency of E3 ligase library screening, saves small molecule screening costs, and improves the development of PROTAC compounds. efficiency.
Smart Images

Figure CN118515785B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a fusion protein, a ubiquitination system containing the fusion protein, and applications thereof. Background Art
[0002] PROTAC (proteolysis-targeting chimeras) use bispecific molecules to link E3 ligases to target proteins, thereby mimicking the binding of E3 ligases to natural substrates and degrading selected target proteins (such as proteasomes) through ubiquitination-mediated proteasomal degradation. Figure 1 as shown).
[0003] CRBN and VHL are two E3 ligases widely used in the development of PROTAC molecules, but they have limitations in effectively degrading certain target proteins. Expanding the library of E3 ligases for PROTAC development is crucial for the development of PROTAC drugs, but there are more than 600 E3 ligases in the human body, most of which have not developed specific binding small molecules. Considering the long cycle and high cost of small molecule development, if the ability of E3 ligases to degrade selected target proteins can be evaluated in advance without specific small molecules or PROTAC molecules based on these small molecules, E3 ligases with PROTAC development potential can be selected for subsequent development. To this end, some new detection methods have been developed. Such as Figure 2 As shown, the E3 ligase reporter system (ACS Chem Biol. 2017 Oct 20;12(10):2570) replaces the substrate recognition domain of the E3 ligase with the HaloTag tag protein, and fuses the target protein with the FKBP tag protein, and then uses a PROTAC molecular tool compound library with HaloTag and FKBP to test the degradation efficiency of the E3 ligase for the target protein. The BioPROTAC assay method (PNAS2020 Mar 17;117(11):5791-5800) replaces the substrate recognition domain of E3 with a Nanobody (nanobody / VHH, an antigen-specific recognition fragment of a small antibody found in camels and alpacas, equivalent to the scFv fragment of a general antibody) that specifically recognizes GFP, and fuses the target protein with the GFP protein. The GFP-Nanobody interaction will mimic the binding of the E3 ligase to its natural substrate, thereby inducing ubiquitination and degradation of the protein.
[0004] However, these previously designed detection methods have a flaw: they all require replacing the entire substrate recognition domain of the E3 ligase with a Halo-tagged protein / GFP Nanobody, which destroys the original structure of the E3 ligase. For some E3 ligases (such as BTRC), such a replacement is feasible because the WD40 domain of its substrate recognition domain does not participate in the binding with the rest of the E3 complex. However, for other E3 ligases such as CRL4 E3 ligase (including CRBN), the formation of a stable E3 complex requires a complete substrate recognition domain (such as Figure 3 As shown in Figure 2, the replacement of this overall protein domain will reduce the binding of the E3 ligase to the E3 complex, thereby inhibiting the degradation of the target protein. In fact, according to literature data, the CRL4 E3 ligase CRBN did not show degradation efficiency in the BioPROTAC detection method, which is inconsistent with the actual situation that CRBN can widely degrade non-substrate proteins through PROTAC molecules. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the defect of damaging the E3 ligase substrate recognition domain when constructing an E3 ligase library in the prior art, and provide a fusion protein, a ubiquitination system containing the fusion protein and its application.
[0006] The inventors designed a small antigen peptide to be added to the random coil structure in the protein structure at the substrate binding site of the E3 ligase, and connected the nanobody that specifically recognizes the antigen to the target protein. Because the antigen sequence is added to the random coil structure, it does not change the overall structure of the E3 ligase, and therefore does not affect its binding to the E3 complex, making it possible to detect CRL4 E3 ligase and other E3 ligases with similar characteristics. The interaction between the nanobody and the antigen peptide can simulate the E3 ligase-substrate interaction, thereby evaluating the ability of the E3 ligase to degrade specific target proteins.
[0007] In theory, any specific nanobody-antigen peptide binding pair (or extended to protein-peptide binding pairs) can be applied to this detection method. However, because the added antigen sequence is in the middle position of the protein, and the binding of some nanobodies to antigen peptides requires certain structural changes in the antigen peptides (such as from irregular curling to α-helix or β-pleated sheet), this increases some torsion, which may inhibit binding or cause protein denaturation. Therefore, the inventors tend to select antigen peptides that can spontaneously fold into α-helix during expression, because such structures will not produce obvious structural changes when combined with nanobodies. In addition, some nanoantibodies are rich in disulfide bonds, cannot exist stably in cells, and are not suitable for this detection method. By analyzing the existing nanoantibody-antigen peptide pairs that meet the above standards, an antigen peptide with 13 amino acids named ALFA (SRLEEELRRRLTE, SEQ ID NO: 1) was selected. This is a peptide that can form an α-helical structure on its own and can specifically bind to a nanobody named NbALFA, and the binding constant reaches the picomolar level (Nat Commun 2019 10: 4403-4403; WO2020053239A1). By analyzing the structure of the E3 ligase, the inventors inserted the ALFA peptide into the loop region of the substrate binding domain of several E3 ligases. At the same time, in order to prevent ubiquitination from occurring on the nanobody, the two lysines on the surface of NbALFA were mutated to arginine and named NbALFAK2R, and fused to the target protein to be studied. The inventors also fused a modified HiBit tag (Promega) into the target protein for quantitative determination of the target protein in the cell. At the same time, the transfected cells were treated with the proteasome inhibitor MG132 to determine whether the changes in the target protein level were achieved through the proteasome degradation pathway.
[0008] The present invention solves the above technical problems through the following technical solutions.
[0009] The first aspect of the present invention provides a fusion protein, which comprises an E3 ligase and a polypeptide inserted into the E3 ligase; wherein the polypeptide is inserted into the random coil structure of the substrate recognition domain of the E3 ligase and retains the structure of the substrate recognition domain.
[0010] In some embodiments of the present invention, the polypeptide can spontaneously form an α-helical structure and does not change the structure of the substrate recognition domain after binding to a ligand of a targeting polypeptide.
[0011] In some embodiments of the present invention, the E3 ligase is selected from the group consisting of E3 ubiquitin ligases of the SCF, CRL4, APC / C and CRL3 families.
[0012] In some embodiments of the present invention, the E3 ligase is selected from BTRC, FBXW2, FBXW4, FBXW5, FBXW7, FBXW8, FBXW9, FBXW10, FBXW11, FBXW12 (SCF family); CRBN, COP1, DCAF1, DCAF2, DCAF3, DCAF4, DCAF5, DCAF6, DCAF7, DCAF8, DCAF9, DCAF10, DCAF11, DCAF12, DCAF13, DCAF14 (CRL4 family); CDC20 (APC / C family) and KEAP1 (CRL3 family).
[0013] In some embodiments of the present invention, the length of the polypeptide is 5-15 aa, for example, 10-15 aa.
[0014] In some embodiments of the present invention, the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 1.
[0015] In some embodiments of the present invention, the amino acid sequence of the polypeptide is shown in SEQ ID NO: 1.
[0016] In some embodiments of the present invention, the polypeptide is a modified polypeptide.
[0017] In some embodiments of the present invention, the modification is the addition of a single proline at the N-terminus and the C-terminus of the polypeptide, respectively.
[0018] In some embodiments of the present invention, the N-terminus and the C-terminus of the polypeptide are respectively inserted into the E3 ligase via a linker.
[0019] In some embodiments of the present invention, the linker is a GS linker.
[0020] In some embodiments of the present invention, the linker comprises an amino acid sequence as shown in any one of SEQ ID NOs: 9-12.
[0021] In some embodiments of the present invention, the fusion protein has an amino acid sequence as shown in any one of SEQ ID NOs: 13-40 or having at least 80%, at least 82%, at least 84%, at least 85%, at least 86%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.2%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.8%, or 99.9% sequence identity with any one of SEQ ID NOs: 13-40.
[0022] The second aspect of the present invention provides an application of the fusion protein as described in the first aspect in constructing a ubiquitin ligase screening platform, constructing a PROTAC screening platform, and regulating the intracellular expression level of a protein.
[0023] In some embodiments of the present invention, the polypeptide in the fusion protein binds to a ligand that targets the polypeptide, and the ligand is connected to the target protein, thereby reducing the spatial distance between the E3 ligase and the target protein, so that the target protein carries the ubiquitination mark of the E3 ligase for ubiquitination degradation, and the ligand is a ligand that is immune to ubiquitination.
[0024] In some embodiments of the present invention, the ligand is a protein ligand.
[0025] In some embodiments of the present invention, the ligand is an antibody or an antigen-binding fragment.
[0026] In some embodiments of the present invention, the surface of the non-antigen recognition domain of the antibody or antigen binding domain thereof has no free lysine.
[0027] In some embodiments of the present invention, lysine on the surface of the non-antigen recognition domain of the antibody or antigen-binding domain thereof is replaced with arginine.
[0028] In some embodiments of the present invention, the antibody is a single domain antibody.
[0029] In some embodiments of the present invention, the antibody is a heavy chain antibody.
[0030] In some embodiments of the present invention, the ligand is a heavy chain antibody, which comprises a CDR1 with an amino acid sequence as shown in SEQ ID NO: 2, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 3, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 4.
[0031] In some embodiments of the present invention, the heavy chain antibody comprises a variable region of an amino acid sequence as shown in SEQ ID NO: 6 or an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.2%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.8%, or 99.9% identical to SEQ ID NO: 6.
[0032] In some embodiments of the present invention, the target protein is further linked to a tag protein; the tag protein is preferably a tag protein that is free from ubiquitination and can be used for quantitative detection of the target protein.
[0033] In some embodiments of the present invention, the tag protein is HiBit; the HiBit is preferably a K2R variant, comprising an amino acid sequence as shown in SEQ ID NO: 8.
[0034] The third aspect of the present invention provides a ubiquitination system, which comprises the fusion protein as described in the first aspect, a ligand targeting the polypeptide in the fusion protein, and a target protein;
[0035] Wherein, the ligand is a ligand that is free from ubiquitination; the target protein is connected to the ligand of the targeting polypeptide, and the spatial distance between the E3 ligase and the target protein is reduced, so that the target protein is recognized by the substrate recognition domain of the E3 ligase and then binds to the E3 ligase, and the target protein carries the ubiquitination tag of the E3 ligase to achieve ubiquitination degradation.
[0036] In some embodiments of the present invention, the ligand is a protein ligand that specifically binds to the polypeptide.
[0037] In some embodiments of the present invention, the ligand is an antibody or an antigen binding domain thereof.
[0038] In some embodiments of the present invention, the antibody is a heavy chain antibody or a scFv.
[0039] In some embodiments of the present invention, the antibody is a single domain antibody.
[0040] In some embodiments of the present invention, the antibody is a heavy chain antibody.
[0041] In some embodiments of the present invention, the ligand is a heavy chain antibody, which comprises a CDR1 with an amino acid sequence as shown in SEQ ID NO: 2, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 3, and a CDR3 with an amino acid sequence as shown in SEQ ID NO: 4.
[0042] In some embodiments of the present invention, the heavy chain antibody comprises a variable region of an amino acid sequence as shown in SEQ ID NO: 6 or an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.2%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.8%, or 99.9% identical to SEQ ID NO: 6.
[0043] In some embodiments of the present invention, the surface of the non-antigen recognition domain of the antibody or antigen binding domain thereof has no free lysine.
[0044] In some embodiments of the present invention, lysine on the surface of the non-antigen recognition domain of the antibody or antigen-binding domain thereof is replaced with arginine.
[0045] In some embodiments of the present invention, the target protein is further linked to a tag protein; the tag protein is a tag protein that is free from ubiquitination.
[0046] In some specific embodiments of the present invention, the tag protein is HiBit; the HiBit is preferably a K2R variant, comprising an amino acid sequence as shown in SEQ ID NO: 8.
[0047] The fourth aspect of the present invention provides a polynucleotide encoding the fusion protein as described in the first aspect or the ubiquitination system as described in the third aspect.
[0048] The fifth aspect of the present invention provides a recombinant expression vector, which comprises the polynucleotide as described in the fourth aspect.
[0049] In some embodiments of the present invention, the recombinant expression vector is a plasmid backbone, such as pcDNA3.1.
[0050] The sixth aspect of the present invention provides a transformant, which comprises the polynucleotide as described in the fourth aspect or the recombinant expression vector as described in the fifth aspect.
[0051] The seventh aspect of the present invention provides a method for preparing a fusion protein, the method comprising culturing the transformant as described in the sixth aspect to obtain the fusion protein.
[0052] The eighth aspect of the present invention provides a kit, which comprises the fusion protein as described in the first aspect, the ubiquitination system as described in the third aspect, the polynucleotide as described in the fourth aspect, the recombinant expression vector as described in the fifth aspect, or the transformant as described in the sixth aspect.
[0053] The ninth aspect of the present invention provides a method for evaluating an E3 ligase, the method comprising evaluating the degradation efficiency of the E3 ligase on a target protein by the ubiquitination system as described in the third aspect;
[0054] Among them, in the ubiquitination system, the polypeptide reduces the spatial distance between the E3 ligase and the target protein by binding to the ligand of the targeting polypeptide, so that the target protein carries the ubiquitination tag of the E3 ligase for ubiquitination degradation.
[0055] The tenth aspect of the present invention provides an evaluation system for an E3 ligase, the evaluation system comprising an input module, a reaction analysis module and a judgment output module; wherein the input module inputs the ubiquitination system as described in the third aspect into the reaction analysis module, the ubiquitination system ubiquitinates the target protein in the reaction analysis module, and analyzes the content data of the target protein before and after ubiquitination and transmits it to the judgment output module; the judgment output module judges the degradation effect of the used E3 ligase on the target protein according to the content data of the target protein before and after ubiquitination;
[0056] Among them, when the content of the target protein after ubiquitination reaches 80% of the content before ubiquitination, and the reduction of the target protein content can be inhibited by a protease inhibitor, it is judged that the E3 ligase has a degradation effect on the target protein, otherwise the E3 ligase has no degradation effect on the target protein.
[0057] The eleventh aspect of the present invention provides a use of the fusion protein as described in the first aspect, the ubiquitination system as described in the third aspect, the polynucleotide as described in the fourth aspect, the recombinant expression vector as described in the fifth aspect, the transformant as described in the sixth aspect, the kit as described in the eighth aspect, or the evaluation system as described in the tenth aspect in constructing a ubiquitin ligase screening platform, constructing a PROTAC screening platform, and regulating the intracellular expression level of a protein.
[0058] The twelfth aspect of the present invention provides an application of a polypeptide as shown in SEQ ID NO: 1 in constructing a ubiquitin ligase screening platform, constructing a PROTAC screening platform, and regulating the intracellular expression level of a protein.
[0059] The thirteenth aspect of the present invention provides an antibody or an antigen binding domain thereof for use in constructing a ubiquitin ligase screening platform, constructing a PROTAC screening platform, and regulating the intracellular expression level of a protein;
[0060] The antibody or its antigen-binding domain comprises a heavy chain variable region, wherein the heavy chain variable region comprises a CDR1 having an amino acid sequence as shown in SEQ ID NO: 2, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 3, and a CDR3 having an amino acid sequence as shown in SEQ ID NO: 4.
[0061] In some embodiments of the invention, the variable region comprises an amino acid sequence as shown in SEQ ID NO: 6 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.2%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.8%, or 99.9% sequence identity to SEQ ID NO: 6.
[0062] In some embodiments of the present invention, the antibody or antigen-binding domain thereof is an antibody or antigen-binding domain thereof that is free from ubiquitination.
[0063] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0064] The reagents and raw materials used in the present invention are commercially available.
[0065] The positive and progressive effects of the present invention are:
[0066] The fusion protein and ubiquitination system of the present invention provide a universal method for detecting the degradation spectrum of E3 ubiquitin ligase against non-natural substrate proteins, which can detect whether E3 ubiquitin ligase has a degradation effect on a target protein before small molecule screening and PROTAC compound development, thereby saving screening costs and improving development efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] Figure 1 Schematic diagram of the principles of E3 ligase degradation of natural substrate proteins and PROTAC-mediated E3 ligase degradation of non-natural substrate proteins.
[0068] Figure 2 Schematic diagram of the E3 ligase reporter system and BioPROTAC detection method using HaloTag tags in the literature.
[0069] Figure 3 Schematic diagram of the protein three-dimensional structure of the interaction between the substrate recognition WD40 domain of DCAF1 and DDB1.
[0070] Figure 4 This is a schematic diagram of the design of a method for detecting the degradation selectivity of E3 ligase for target protein based on nanobody-antigen peptide pairs, taking BTRC as an example of the present invention.
[0071] Figure 5 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase BTRC (SEQID NO: 13) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0072] Figure 6 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase FBXW2 (SEQID NO: 14) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0073] Figure 7 Schematic diagram of the degradation profile of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase FBXW4 (SEQID NO: 15) fused to a control peptide (not bound to nanoantibodies) or an ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitors.
[0074] Figure 8 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase FBXW5 (SEQID NO: 16) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitors.
[0075] Fig. 9 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase FBXW7 (SEQID NO: 17) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitors.
[0076] Fig.10 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase FBXW8 (SEQID NO: 18) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitors.
[0077] Fig.11 Schematic diagram of the degradation spectrum results of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase FBXW9 (SEQID NO: 19) fused with a control peptide (not bound to the nanobody) or an ALFA peptide.
[0078] Fig.12 Schematic diagram of the degradation spectrum of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase FBXW10 (SEQ ID NO: 20) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0079] Fig.13 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase FBXW11 (SEQ ID NO: 21) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0080] Fig.14 Schematic diagram of the degradation spectrum of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase FBXW12 (SEQ ID NO: 22) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0081] Fig.15 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase CRBN (SEQID NO: 23) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0082] Fig.16 Schematic diagram of the degradation spectrum results of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase COP1 (SEQID NO: 24) fused with a control peptide (not bound to the nanobody) or an ALFA peptide.
[0083] Fig.17 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF1 (SEQID NO: 25) fused to a control peptide (not bound to nanoantibodies) or an ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitors co-incubation.
[0084] Fig.18 Schematic diagram of the degradation spectrum of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF2 (SEQID NO: 26) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0085] Fig.19 The figure shows the degradation profiles of different target proteins and NbALFAK2R fusion proteins in the presence of control peptides (not bound to nanobodies) or E3 ligase DCAF3 (SEQ ID NO: 27) fused to ALFA peptides, and the changes in relative protein abundance in the presence or absence of proteasome inhibitors.
[0086] Fig. 20 Schematic diagram of the degradation spectrum results of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF4 (SEQID NO: 28) fused with a control peptide (not bound to the nanobody) or an ALFA peptide.
[0087] Fig.21Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF5 (SEQID NO: 29) fused to a control peptide (not bound to nanoantibodies) or an ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0088] Fig. 22 Schematic diagram of the degradation profile of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF6 (SEQID NO: 30) fused to a control peptide (not bound to nanoantibodies) or an ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitors.
[0089] Fig.23 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF7 (SEQID NO: 31) fused to a control peptide (not bound to nanoantibodies) or an ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0090] Fig.24 Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF8 (SEQID NO: 32) fused to a control peptide (not bound to nanoantibodies) or an ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0091] Fig.25 Schematic diagram of the degradation spectrum of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF9 (SEQID NO: 33) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0092] Fig.26 Schematic diagram of the degradation profile of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF10 (SEQ ID NO: 34) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0093] Fig. 27 Schematic diagram of the degradation spectrum of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF11 (SEQ ID NO: 35) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0094] Fig.28Schematic diagram of the degradation profiles of different target proteins and NbALFAK2R fusion protein in the presence of a control peptide (not bound to the nanobody) or the E3 ligase DCAF12 (SEQ ID NO: 36) fused to the ALFA peptide, and the changes in relative protein abundance in the presence / absence of proteasome inhibitor co-incubation.
[0095] Fig.29 Schematic diagram of the degradation profile of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF13 (SEQ ID NO: 37) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0096] Fig.30 Schematic diagram of the degradation spectrum results of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase DCAF14 (SEQ ID NO: 38) fused to a control peptide (not bound to the nanobody) or an ALFA peptide.
[0097] Fig.31 Schematic diagram of the degradation spectrum results of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase CDC20 (SEQID NO: 39) fused with a control peptide (not bound to the nanobody) or an ALFA peptide.
[0098] Fig.32 Schematic diagram of the degradation spectrum results of different target proteins and NbALFAK2R fusion protein in the presence of E3 ligase KEAP1 (SEQID NO: 40) fused with a control peptide (not bound to the nanobody) or an ALFA peptide. DETAILED DESCRIPTION
[0099] definition
[0100] The term "ubiquitin ligase" refers to a family of proteins that promote the transfer of ubiquitin to specific substrate proteins and target substrate proteins for degradation. For example, cerebellin is an E3 ubiquitin ligase protein that causes ubiquitin to be attached to lysine on a target protein alone or in combination with an E2 ubiquitin conjugating enzyme and then targets specific protein substrates for degradation by the proteasome. Therefore, E3 ubiquitin ligases alone or in combination with E2 ubiquitin conjugating enzymes are the cause of ubiquitin transfer to target proteins. In general, ubiquitin ligases participate in polyubiquitination so that a second ubiquitin is attached to a first ubiquitin; a third ubiquitin is attached to a second ubiquitin, and so on. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to monoubiquitination, in which only a single ubiquitin is added to a substrate molecule by a ubiquitin ligase. Monoubiquitinated proteins are not targeted to the proteasome for degradation, but may instead change in their cellular location or function, such as by binding to other proteins with a domain that can bind ubiquitin.
[0101] In the present invention, ubiquitin-dependent proteolysis is a major catabolic pathway used by eukaryotic cells to degrade intracellular proteins. There are three types of enzymes that synergistically catalyze protein ubiquitination: E1 ubiquitin activating enzyme, E2 ubiquitin coupling enzyme, and E3 ubiquitin ligase (see Hochstrasser (1996) Annu Rev. Genet 30: 40539). E1 and E2 are mainly involved in the activation and transfer of ubiquitin, and the substrate specificity of the ubiquitin pathway is completed by E3 ubiquitin ligase.
[0102] As used in the present invention, "ubiquitination-free" means that the target protein cannot be recognized by the ubiquitin ligase due to the lack of the recognizable element of the ubiquitin ligase, thereby avoiding ubiquitination and degradation.
[0103] The "antibody" used in the present invention refers to a dipeptide chain structure composed of at least two identical heavy chains connected by interchain disulfide bonds. The "antigen binding fragment" or "antigen binding domain" refers to the smallest antibody fragment with antigen binding activity.
[0104] In the present invention, "single domain antibody", "single region antibody" and "nano antibody" are used interchangeably. The single domain antibody may include an antibody whose complementary determining region is a component of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally lacking light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies, and single domain scaffolds other than those derived from antibodies. The single domain antibody may be any antibody of the prior art, or any single domain antibody in the future. The single domain antibody may be derived from any species, including but not limited to mice, humans, camels, alpacas, fish, goats, rabbits and cattle. In some instances, the single domain antibody is a naturally occurring single domain antibody, referred to as a heavy chain antibody lacking a light chain. For clarity purposes, this variable domain derived from a heavy chain antibody naturally lacking a light chain is referred to as a VHH or single region antibody in the present invention to distinguish it from the conventional VH of a four-chain immunoglobulin. This VHH molecule may be derived from antibodies produced in species of the Camelidae family (e.g., camels, alpacas, dromedaries, llamas and guanacos). Species other than camels can produce heavy chain antibodies that naturally lack light chains, and such VHHs are also included in the scope of the present invention. Similar to the VH and VL regions, the VHH region can be further divided into hypervariable regions, called "complementarity determining regions" (CDRs), with more conservative regions inserted in between, called "framework regions" (FRs). The scope of the framework region and CDRs has been defined in a variety of ways.
[0105] As used herein, the term "sequence identity" refers to the sequence similarity between two polynucleotide sequences or between two polypeptides. When the positions in the two comparison sequences are occupied by the same base or amino acid monomer subunit, for example, if every position of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent identity between the two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100. For example, when the sequences are optimally aligned, if 6 out of 10 positions in the two sequences are matched or homologous, then the two sequences are 60% homologous. In general, comparison is performed when the two sequences are aligned to obtain the maximum percent identity.
[0106] As used in this article, the term "vector" generally refers to a nucleic acid molecule that can replicate itself in a suitable host, which transfers the inserted nucleic acid molecule into a host cell and / or between host cells. The term may include a vector that is primarily used to insert DNA or RNA into a cell, a vector that is primarily used to replicate DNA or RNA, and an expression vector that is used to transcribe and / or translate DNA or RNA. Also included are vectors that provide more than one of the above functions. An "expression vector" is a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. An "expression system" generally means a suitable host cell that includes an expression vector that can produce a desired expression yield.
[0107] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0108] The NbALFAK2R nanobody is an antibody obtained by mutating two lysines in the framework region of the NbALFA nanobody to arginines, and its antibody sequence is shown in Table 1 below.
[0109]
[0110] The amino acid sequence of the HiBitK2R tag used in the example is shown in SEQ ID NO: 8, and the amino acid sequence of the original HiBit tag is shown in SEQ ID NO: 7.
[0111] Example 1
[0112] HEK293T cells used in this example were purchased from the American Type Culture Collection (ATCC, USA) and cultured in DMEM (Gibco 11995-073) and 10% fetal bovine serum (FBS, Gibco 10099-141C). The main reagents used included: Lipofectamine 3000 transfection reagent (Invitrogen L3000008), Opti-MEM culture medium (Gibco 31985062), Typsin cell digestion solution (Gibco 25200114), HiBit reagent (Nano-Glo® HiBiT lysis detection system, Promega N3040), MG132 compound (Selleck S2619), DMSO (Sigma D2650-5X10ML).
[0113] One day before transfection, HEK293T cells were plated in 48-well cell culture plates so that the density was 70%-80% at the time of transfection. On the day of transfection, 0.06 µg of E3 ligase-ALFA peptide fusion protein (SEQ ID NO: 13-40) or E3 ligase-negative control random peptide (control peptide, AVERYLKDQQLLGIW (SEQ ID NO: 41), which does not bind to the nanobody NbALFAK2R) fusion protein and 0.06 µg of plasmid expressing HiBitK2R-target protein-nanobody fusion protein (preparation method refers to https: / / assets.thermofisher.cn / TFS-Assets%2FLSG%2Fmanuals%2Fpcdna3_1_man.pdf, the plasmid backbone is pcDNA3.1, and the protein sequence to be expressed is inserted through the 3' HindIII and 5' EcoRI sites) were mixed in 25 µL Opti-MEM medium, and then 0.24 µL P3000 was added to mix, and then 25 µL of Lipofectamine 3000 diluted with 1.25 µL was added. Opti-MEM medium was added to a 48-well cell culture plate after incubation at room temperature for 15 minutes. After 6 hours of transfection, cells were digested with Typsin, the medium was resuspended to 1 mL, and 35 µL was taken to a deep-well 384-well cell culture plate. 24 hours after transfection, 20 µL of HiBit reagent was added to each well, shaken, and incubated at room temperature for 20 min to read the luminescence intensity.
[0114] For the positive group (expressing HiBitK2R-target protein-nanoantibody fusion protein, target protein HiBit signal reduced by 20%), a proteasome inhibition experiment will be further performed to verify whether the change in target protein level is achieved through the proteasome degradation pathway. The plasmid transfection experimental steps are the same as before. After 6 hours of transfection, the cells are digested with Typsin, the culture medium is resuspended to 1mL, and 70 nL 2.5mM MG132 (proteasome inhibitor) or DMSO (negative control) is added, and 35 µL is taken to a deep-well 384-well cell culture plate. 24 hours after transfection, 20 µL of HiBit reagent is added to each well, shake well, and incubate at room temperature for 20 min to read the luminescence intensity.
[0115] Test results
[0116] Using a variety of protein substrates fused to NbALFAK2R (including β-catenin, KRAS G12C, RAF1, FGFR1, FGFR3, SHP2, WDR5, GATA2, MCL1, Myc, SMARCA2) to evaluate the protein degradation profiles of 28 E3 ligases belonging to the SCF family, CRL4 family, APC / C family, and CRL3 family, such as BTRC, CRBN, FBXW7, and COP1. Figure 4 As shown, ALFA antigen and negative control random peptide (control peptide) are fused to the substrate recognition region of three E3 ligases to simulate the binding of natural substrates to them. Among them, β-catenin is the natural substrate of BTRC, and CRBN can effectively degrade RAF1 through the combination of nanoantibodies and antigens. The above E3 ligase-substrate protein combination is used as a positive control in the assay. The experimental results show that BTRC, CRBN and FBXW7 fused with ALFA can effectively degrade a variety of target proteins. In addition to showing degradation of the natural substrate β-catenin, BTRC also shows degradation of KRAS G12C , RAF1, FGFR3, SHP2, WDR5, GATA2, and SMARCA2, and the degradation depends on the proteasome pathway (e.g. Figure 5 FBXW7 showed an inhibitory effect on KRAS G12C , RAF1, FGFR1, FGFR3, SHP2, GATA2, and SMARCA4, and the degradation depends on the proteasome pathway (e.g. Fig. 9 As a homologous protein of BTRC, FBXW11 exhibits a degradation profile similar to that of BTRC (as shown in Fig.13 CRBN has a degradation effect on all the target proteins tested, and the degradation depends on the proteasome pathway (KRAS G12C Doubtful, such as Fig.15 CRBN showed the broadest degradation profile among all the E3 ligases tested, which is consistent with the broad degradation profile of PROTACs developed for CRBN. Other E3 ligases tested did not show any degradation effect on the tested target proteins, or only had degradation effects on individual target proteins (e.g. Figure 6-8 , 10-12, 14, 16-32), indicating that the degradation spectrum of these E3 ligases is narrow and may not be suitable for the development of PROTAC molecules targeting them.
Claims
1. A fusion protein, characterized in that The fusion protein comprises an E3 ligase and a polypeptide inserted into the E3 ligase; wherein the polypeptide is inserted into the random coil structure of the substrate recognition domain of the E3 ligase and retains the structure of the substrate recognition domain; The polypeptide comprises the amino acid sequence shown in SEQ ID NO: 1; The E3 ligase is BTRC, CRBN, FBXW7 or FBXW11; The N-terminus and the C-terminus of the polypeptide are respectively inserted into the E3 ligase via a linker; The polypeptide has a single proline added to the N-terminus and the C-terminus respectively; the amino acid sequence of the fusion protein is shown in SEQ ID NO: 13, 17, 21 or 23; The insertion position corresponds to positions 303-333 of the amino acid sequence shown in SEQ ID NO: 13; or The insertion position corresponds to positions 692-720 of the amino acid sequence shown in SEQ ID NO: 17; or The insertion position corresponds to positions 240-268 of the amino acid sequence shown in SEQ ID NO: 21; or The insertion position corresponds to positions 130-158 of the amino acid sequence shown in SEQ ID NO:
23.
2. The fusion protein according to claim 1, characterized in that The linker is a GS linker.
3. The fusion protein according to claim 2, characterized in that The linker has an amino acid sequence as shown in any one of SEQ ID NOs: 9-12.
4. Use of the fusion protein according to any one of claims 1 to 3 in constructing a ubiquitin ligase screening platform or a PROTAC screening platform; The polypeptide in the fusion protein binds to the ligand targeting the polypeptide, and the ligand is connected to the target protein, thereby reducing the spatial distance between the E3 ligase and the target protein, so that the target protein carries the ubiquitination tag of the E3 ligase for ubiquitination degradation; The ligand is a ligand that is protected from ubiquitination; The ligand is an antibody, and the antibody is a heavy chain antibody; The heavy chain antibody comprises a CDR1 having an amino acid sequence as shown in SEQ ID NO: 2, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 3, and a CDR3 having an amino acid sequence as shown in SEQ ID NO:
4.
5. The use according to claim 4, characterized in that The surface of the non-antigen recognition domain of the antibody has no free lysine.
6. The use according to claim 5, characterized in that The surface lysine of the non-antigen recognition domain of the antibody is replaced with arginine.
7. The use according to claim 4, characterized in that The heavy chain antibody comprises a variable region having an amino acid sequence as shown in SEQ ID NO: 6 or having at least 90% sequence identity with SEQ ID NO:
6.
8. The use according to claim 4, characterized in that The target protein is also linked to a tag protein; the tag protein is used for quantitative detection of the target protein and is protected from ubiquitination.
9. The use according to claim 8, characterized in that The tag protein is HiBit; the HiBit comprises the amino acid sequence shown in SEQ ID NO:
8.
10. A ubiquitination system, characterized in that The ubiquitination system consists of the fusion protein according to any one of claims 1 to 3, a ligand targeting the polypeptide in the fusion protein, and a target protein; Wherein, the ligand is a ligand that is free from ubiquitination; the target protein is connected to the ligand of the targeting polypeptide, and the spatial distance between the E3 ligase and the target protein is reduced, so that the target protein is recognized by the substrate recognition domain of the E3 ligase and then binds to the E3 ligase, and the target protein carries the ubiquitination tag of the E3 ligase to achieve ubiquitination degradation; The ligand is a heavy chain antibody, which comprises a CDR1 with an amino acid sequence as shown in SEQ ID NO: 2, a CDR2 with an amino acid sequence as shown in SEQ ID NO: 3, and a CDR3 with an amino acid sequence as shown in SEQ ID NO:
4.
11. The ubiquitination system according to claim 10, characterized in that The surface of the non-antigen recognition domain of the antibody has no free lysine.
12. The ubiquitination system according to claim 11, characterized in that The surface lysine of the non-antigen recognition domain of the antibody is replaced with arginine.
13. The ubiquitination system according to claim 10, wherein The heavy chain antibody comprises a variable region having an amino acid sequence as shown in SEQ ID NO: 6 or having at least 90% sequence identity with SEQ ID NO:
6.
14. The ubiquitination system according to claim 10, characterized in that The target protein is also linked to a tag protein; the tag protein is a tag protein that is protected from ubiquitination.
15. The ubiquitination system according to claim 14, wherein The tag protein is HiBit; the HiBit comprises the amino acid sequence shown in SEQ ID NO:
8.
16. A polynucleotide, characterized in that The polynucleotide encodes the fusion protein according to any one of claims 1 to 3 or the ubiquitination system according to any one of claims 10 to 15.
17. A recombinant expression vector, characterized in that: The recombinant expression vector comprises the polynucleotide according to claim 16.
18. The recombinant expression vector according to claim 17, characterized in that The recombinant expression vector is a plasmid skeleton.
19. A transformant, characterized in that: The transformant comprises the polynucleotide according to claim 16, or the recombinant expression vector according to claim 17 or 18.
20. A kit, characterized in that: The kit comprises the fusion protein according to any one of claims 1 to 3, the ubiquitination system according to any one of claims 10 to 15, the polynucleotide according to claim 16, the recombinant expression vector according to claim 17 or 18, or the transformant according to claim 19.
21. A method for evaluating an E3 ligase, characterized in that: The method comprises evaluating the degradation efficiency of the target protein by the E3 ligase through the fusion protein according to any one of claims 1 to 3 or the ubiquitination system according to any one of claims 10 to 15; Among them, in the ubiquitination system, the polypeptide reduces the spatial distance between the E3 ligase and the target protein by binding to the ligand of the targeting polypeptide, so that the target protein carries the ubiquitination tag of the E3 ligase for ubiquitination degradation.
22. An evaluation system for E3 ligase, characterized in that: The evaluation system comprises an input module, a reaction analysis module and a judgment output module; wherein the input module inputs the ubiquitination system as described in any one of claims 10 to 15 into the reaction analysis module, the ubiquitination system ubiquitinates the target protein in the reaction analysis module, and analyzes the content data of the target protein before and after ubiquitination and transmits it to the judgment output module; the judgment output module judges the degradation effect of the used E3 ligase on the target protein according to the content data of the target protein before and after ubiquitination; Among them, when the content of the target protein after ubiquitination is lower than 80% of the content before ubiquitination, and the reduction of the target protein content can be inhibited by a protease inhibitor, it is judged that the E3 ligase has a degradation effect on the target protein, otherwise the E3 ligase has no degradation effect on the target protein.
23. Use of the ubiquitination system according to any one of claims 10 to 15, the polynucleotide according to claim 16, the recombinant expression vector according to claim 17 or 18, the transformant according to claim 19, the kit according to claim 20 or the evaluation system according to claim 22 in constructing a ubiquitin ligase screening platform or a PROTAC screening platform.
24. Use of the fusion protein according to any one of claims 1 to 3, the ubiquitination system according to any one of claims 10 to 15, the polynucleotide according to claim 16, the recombinant expression vector according to claim 17 or 18, the transformant according to claim 19, the kit according to claim 20 or the evaluation system according to claim 22 in preparing a reagent for regulating the intracellular expression level of a protein.
